Cardiology Unit, Azienda Ospedaliero Universitaria Di Ferrara, Via Aldo Moro 8, 44124, Cona, FE, Italy.
Cardiovasc Drugs Ther. 2024 Feb;38(1):151-161. doi: 10.1007/s10557-022-07351-x. Epub 2022 Jun 9.
Coronary vasomotor dysfunction embraces two specific clinical entities: coronary (micro)vascular spasm and microvascular dysfunction. The clinical manifestations of these entities are respectively called vasospastic angina (VSA) and microvascular angina (MVA). Over the years, these diseases have become more and more prominent and several studies aimed to investigate the best diagnostic and therapeutic strategies. Patients with coronary vasomotor disorders are often undertreated due to the absence of evidence-based guidelines. The purpose of this overview is to illustrate the various therapeutic options available for the optimized management of these patients.
A Medline search of full-text articles published in English from 1980 to April 2022 was performed. The main analyzed aspects of vasomotor disorders were treatment options. We also performed research on "Clinicaltrial.gov" for ongoing trials.
Coronary (micro)vascular spasm and microvascular dysfunction are clinical entities characterized by high prevalence and clinical representation. Several therapeutic strategies, both innovative and established, are available to optimize treatment and improve the quality of life of these patients.
冠状动脉血管运动功能障碍包括两种特定的临床实体：冠状动脉（微血管）痉挛和微血管功能障碍。这些实体的临床表现分别称为痉挛性心绞痛（VSA）和微血管性心绞痛（MVA）。多年来，这些疾病变得越来越突出，有几项研究旨在探讨最佳的诊断和治疗策略。由于缺乏基于证据的指南，患有冠状动脉血管运动障碍的患者往往得不到充分治疗。本文的目的是说明可用于优化这些患者管理的各种治疗选择。
对 1980 年至 2022 年 4 月发表的英文全文文章进行了 Medline 搜索。对血管运动障碍的主要分析方面是治疗选择。我们还在“Clinicaltrial.gov”上对正在进行的试验进行了研究。
冠状动脉（微血管）痉挛和微血管功能障碍是具有高患病率和临床表现的临床实体。有几种创新和成熟的治疗策略可用于优化治疗并提高这些患者的生活质量。
